Shattuck Labs' ARC platform creates bi-functional fusion proteins for cancer and autoimmune treatments. SL-172154, their flagship candidate, is in Phase 1 trials and shows a promising anti-tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback